BNT162b2 mRNA COVID-19疫苗反应原性:免疫力的关键作用
研究纳入96名医护人员,76%报告任何疫苗反应(第一剂70%,第二剂67%),均不严重。第一剂后全身反应在既往感染者和已有细胞免疫者中更频繁;第二剂后全身反应率在无感染史者和无已有细胞免疫者中分别比第一剂高1.7倍和2.0倍。第一剂反应原性归因于既往COVID-19或交叉反应引发的已有细胞免疫,第二剂后反应原性提示免疫增强效应。
要点
- 96名医护人员中76%报告任何疫苗反应,第一剂70%,第二剂67%,均不严重。
- 第一剂后全身反应在既往感染者中显著更频繁,在已有细胞免疫者中也显著更频繁。
- 无感染史者第二剂后全身反应率是第一剂的1.7倍,无已有细胞免疫者为2.0倍。
核心结论
- BNT162b2疫苗第一剂后反应原性可归因于既往COVID-19或交叉反应引发的已有细胞免疫。
- 第二剂后反应原性提示免疫增强效应。
- 这些数据可能减少对COVID-19疫苗的负面态度。
研究设计与样本
- 研究纳入96名医护人员(HCWs),考察既往SARS-CoV-2特异性细胞免疫对BNT162b2 mRNA COVID-19疫苗反应原性的影响。
- 研究注册于clinicaltrials.gov,注册号NCT04402827。
主要发现
- 96名医护人员中76%报告任何疫苗反应,第一剂后70%,第二剂后67%,均不严重。
- 第一剂后全身反应在既往感染医护人员中比无感染史者显著更频繁,在已有细胞免疫者中比无已有细胞免疫者显著更频繁。
- 无感染史医护人员第二剂后全身反应率是第一剂后的1.7倍,无已有细胞免疫者第二剂后全身反应率是第一剂后的2.0倍。
- 接种前SARS-CoV-2特异性T细胞水平在第一剂后有全身反应者中高于无全身反应者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We examined the impact of pre-existing SARS-CoV-2-specific cellular immunity on BNT162b2 mRNA COVID-19 vaccine reactogenicity. Of 96 healthcare workers (HCWs), 76% reported any vaccine reaction (first dose: 70%, second dose: 67%), none of which was severe. Following first dose, systemic reactions were significantly more frequent among HCWs with past infection than in infection-naïve individuals, and among HCWs with pre-existing cellular immunity than in those without it. The rate of systemic reactions after second dose was 1.7 and 2.0-times higher than after first dose among infection-naïve HCWs and those without pre-existing cellular immunity, respectively. Levels of SARS-CoV-2-specific T-cells before vaccination were higher in HCWs with systemic reactions after the first dose than in those without them. BNT162b2 vaccine reactogenicity after first dose is attributable to pre-existing cellular immunity elicited by prior COVID-19 or cross-reactivity. Reactogenicity following second dose suggests an immunity-boosting effect. Overall, these data may reduce negative attitudes towards COVID-19 vaccines. Study Registration. The study was registered on clinicaltrials.gov, NCT04402827.
引用
- Vizcarra P, Haemmerle J, Velasco H, et al. BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity. Vaccine. 2021. PMID: 34802792. doi:10.1016/j.vaccine.2021.10.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。